Prescription drug · NDA
Cyclophosphamide NDC 55150-271
Cyclophosphamide 1 g/5mL · Injection · Intravenous · Eugia US LLC
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 55150-271-99 | 55150027199 | 1 VIAL, MULTI-DOSE in 1 CARTON (55150-271-99) / 5 mL in 1 VIAL, MULTI-DOSEMarketed from Nov 20, 2023 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Cyclophosphamide
- Generic name (nonproprietary)
- cyclophosphamide
- Active ingredients
- Cyclophosphamide — 1 g/5mL
- Dosage form
- Injection
- Route
- Intravenous
- Labeler
- Eugia US LLC
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 210735
- Marketing start
- Listing expires
- Identifiers
- Product ID 55150-271_f90b3bb0-87cd-4951-9789-34202e2b13dfSPL ID f90b3bb0-87cd-4951-9789-34202e2b13dfSPL set ID 3c1eb470-0bba-457d-94e3-b9508f0d398aRxCUI 2386859, 2568661, 2568663UNII 8N3DW7272PUPC 0355150272013, 0355150271993
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N455150027199followed by a unit qualifier and the quantityPackage 55150-0271-99. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
Malignant Diseases Cyclophosphamide Injection is indicated for the treatment of adult and pediatric patients with: malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin’s disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma multiple myeloma leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration) mycosis fungoides (advanced disease) neuroblastoma (disseminated disease) ade…
Excerpt only. Read the full label for complete information.
Other NDCs under NDA 210735
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Cyclophosphamide | Cyclophosphamide 2 g/10mL | InjectionIntravenous | Eugia US LLC | 55150-272 |
| Cyclophosphamide | Cyclophosphamide 500 mg/2.5mL | InjectionIntravenous | Eugia US LLC | 55150-270 |